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The last decade has seen great strides in the ﬁeld of cancer immunotherapy, especially the treatment of melanoma. Beginning
with the identiﬁcation of cancer antigens, followed by the clinical application of anti-cancer peptide vaccination, it has now been
proven that adoptive T-cell therapy (ACT) using cancer antigen-speciﬁc T cells is the most eﬀective option. Despite the apparent
clinical eﬃcacy of ACT, the timely preparation of a suﬃcient number of cancer antigen-speciﬁc T cells for each patient has been
recognized as its biggest limitation. Currently, therefore, attention is being focused on ACT with engineered T cells produced using
cancer antigen-speciﬁc T-cell receptor (TCR) gene transfer. With regard to human leukemia, ACT using engineered T cells bearing
the leukemia antigen-speciﬁc TCR gene still remains in its infancy. However, several reports have provided preclinical data on TCR
gene transfer using Wilms’ tumor gene product 1 (WT1), and also preclinical and clinical data on TCR gene transfer involving
minor histocompatibility antigen, both of which have been suggested to provide additional clinical beneﬁt. In this review, we
examine the current status of anti-leukemia ACT with engineered T cells carrying the leukemia antigen-speciﬁc TCR gene, and
discuss the existing barriers to progress in this area.
1.Introduction
Adoptive T-cell therapy (ACT) employing autologous engi-
neered T cells produced using cancer antigen-speciﬁc T-cell
receptor (TCR) gene transfer is currently a focus of intense
interest in the ﬁeld of cancer treatment. In combination with
chemoradiationtoreducetheimmunoregulatoryfactorsthat
hamper the eﬃcacy of cancer therapy, Rosenberg and col-
leagues have recently achieved great success in improving the
clinical eﬃcacy of ACT using in vitro-expanded autologous
cancer-speciﬁc T cells [1]. Unfortunately, application of such
ACT to daily clinical practice is largely impeded by the labor-
intensive nature of the procedure, and the diﬃculty involved
in timely preparation of a suﬃcient number of such T cells
for each patient. One recent advance in ACT is the use of
engineered T cells bearing a cancer antigen-speciﬁc TCR
obtained beforehand from an established cytotoxic T-cell
(CTL) clone speciﬁc to a well-established cancer antigen.
Recently, Johnson and colleagues have obtained successful
resultswithantimelanomaACTusingengineeredautologous
T cells that have been expanded in vitro after melanoma
antigen-speciﬁc TCR gene transfer [2]. Despite its feasibility
and safety, ACT with such TCR gene-transferred peripheral
b l o o dl y m p h o c y t e s( P B L )i sl e s se ﬀective than that with in
vitro-expanded autologous tumor-inﬁltrating T cells (TIL),
largely because of the resulting low frequency of target TCR-
expressing lymphocytes among infused cells, in the absence
of selection. Furthermore, preclinical in vivo studies have
suggested that contaminating nontransduced cells might
actively impair the eﬃcacy of such redirected cells [3–5].
On the other hand, the use of ACT with such engineered
T cells against hematological malignancies still remains in its
infancy. Over the last decade, allogeneic hematological stem
cell transplantation (HSCT), which is a form of adoptive
immuno-cell therapy, has successfullyprolonged the survival
time of patients with hematological malignancies. However,2 Journal of Biomedicine and Biotechnology
because its immune reaction is not solely directed against
tumor cells, allogeneic HSCT is associated with substantial
adverse eﬀects, rendering it impractical for elderly patients
and those with comorbidity. On the other hand, following
the identiﬁcation of a series of leukemia antigens, peptide
vaccination is now the main protocol being investigated in
clinical trials, ratherthan ACT withleukemia-speciﬁc T cells,
and this has been shown to confer some additional clinical
beneﬁt [6, 7]. Against this background, several groups,
including our own, have studied the feasibility of applying
engineered T cells bearing Wilms’ tumor gene product
1 (WT1) and minor histocompatibility antigen (HA-1,2)-
speciﬁc TCR genes for the treatment of leukemia [8–11].
Our group has been focusing on ACT with WT1-speciﬁc
TCR gene transfer for leukemia [11]. Here, we overview the
current status of ACT using TCR-gene-transferred T cells,
and discuss the technical issues presently confronting us.
2. CurrentStatus of Cellular Immunotherapy
againstHematological Malignancies
To develop a strategy that is less toxic, but with an eﬃcacy
equal to or greater than that of current therapeutic options
against hematological malignances, cellular immunotherapy
has attracted attention in recent years. The antitumor eﬀect
observed in patients treated successfully with allo-HSCT
(graft versus tumor eﬀect) has underscored the importance
of tumor-speciﬁc CTL, and encouraged the development of
cellular immunotherapy against hematological malignancy
[12,13].Furthermore,thisneedforimmunotherapyhasalso
been emphasized by the fact that even the most successful
molecular target drug for chronic myelogeneous leukemia
(CML), imatinib, cannot induce a cure [14, 15].
Advanced molecular and immunobiological approaches
have allowed the identiﬁcation of various types of tumor-
speciﬁc antigens (TSAs), which discriminate tumor cells
from normal cells, or tumor-associated antigens (TAAs),
which are overexpressed by tumor cells in comparison to
normal cells. CTLs can exert cytotoxicity against tumor cells
via TCR-dependent recognition of human leukocyte antigen
(HLA)/TSA or TAA-derived peptide complex [16, 17]. As a
corollary,itisanticipatedthattherapeuticallyincreasedTSA-
or TAA-speciﬁc CTL in vivo would selectively and durably
eradicate tumor cells within a tolerable and limited range of
adverseeﬀectsagainstnormalcells.Clinicalvaccinationtrials
against leukemia using peptides derived from TSA/TAA have
already been conducted. In particular, such trials involving
RP1 (the determined epitope of proteinase 3), WT1126–134,
and WT1235–243 peptides have been well described [6, 7, 18].
As expected, no serious adverse events were observed in
those clinical trials, and a positive correlation between the in
vivoincreaseofTSA/TAA-speciﬁcCTLsandclinicalresponse
was demonstrated. However, the overall degree of clinical
responsive still remains low, as is the case with peptide
vaccination against solid tumors (total response rate, 2.9%)
[19]. To overcome this clinical insuﬃciency, the feasibility of
adoptive transfer with ex vivo-expanded TSA/TAA-speciﬁc
CTLs or CD4+ T cells has been investigated, and successful
results have also been demonstrated [20–23]. Technical
advances with this treatment have been achieved mainly
against melanoma; successful results have been obtained
using ex-vivo-expanded autologous TIL [20], and by prior
immunodepletion to eradicate immunoregulatory cells [1].
Despitethesesuccesses,broaderapplicationofthistreatment
modality is often largely hampered by lack of success with
the isolation and expansion of TSA/TAA-speciﬁc T cells ex
vivo from individual patients [23]. In an attempt to solve
this critical problem, the feasibility of obtaining engineered
T cells harboring the cancer antigen-speciﬁc TCR gene
from a well-characterized TSA/TAA-speciﬁc CTL clone has
been investigated, and recently success was reported in a
pioneering clinical trial using ACT with autologous T cells
harboring a melanoma antigen-speciﬁc TCR gene [2]. In
parallel with these endeavors for the treatment of solid
tumors, ACT, involving mainly donor lymphocyte infusion
(DLI), has been introduced for the treatment of relapsed
hematological malignancy after allo-HSCT [24]. Although
DLI can provide substantial clinical beneﬁt, it is limited to
patients who have received allo-HSCT and carries a risk of
deterioration to graft-versus host disease (GVHD) because
the infused donor lymphocytes are not characterized before-
hand as being leukemia antigen-speciﬁc [24]. To overcome
such limitations, ACT using ex vivo-expanded autologous
or allogeneic leukemia-speciﬁc T cells has been attempted.
ACT with HLA-identical allogeneic minor antigen (HA-1)-
speciﬁc T cells has been conducted for patients with relapsed
CML after allo-HSCT [25]. As this modality suﬀers from
the same limitations as those associated with the treatment
of solid tumors, the feasibility of using engineered T cells
harboringthetumorantigen-speciﬁcTCRgenehasalsobeen
investigatedforthetreatmentofhematologicalmalignancies.
At present, the potential use of a WT1-speciﬁc TCR gene
[8, 11, 26] and a minor antigen HA-1/2-speciﬁc TCR gene
[9, 10] is being actively examined, but studies are still at the
preclinical stage.
3. Application of EngineeredT Cells
Created by TCR Gene Transfer to
Hematological Malignancy
Steinmetz and colleagues were the ﬁrst to demonstrate that
target antigen speciﬁcity was transferable by transduction of
the TCR gene obtained from a well-characterized CTL clone
[30]. Subsequent studies of TSA/TAA and the establishment
of TSA/TAA-speciﬁc CTL clones with high-aﬃnity TCRs
have led to the belief that for clinical application to ACT, it
would be possible to obtain ex vivo-expanded tumor-speciﬁc
CTLswithhigheﬃcacybytransferofTSA/TAA-speciﬁcTCR
genes to normal T cells. Based on this concept, the feasibility
of transferring TCR genes speciﬁc to well-characterized
TSA/TAA to normal T cells has been examined. These TCRs
were speciﬁc to MART-1, MAGE-A1, MAGE-A4, gp100,
WT1, NY-ESO-1, and minor antigens [8–11, 31–35]. With
the aim of wider application, target TSA/TAA-speciﬁc TCRs
have been centered on HLA-A∗0201 and −A
∗2402 molecule
restriction, both of which are the most prevalent HLA
molecules in both Western and Japanese populations [36,
37]. Target TCR gene transfer has been largely performedJournal of Biomedicine and Biotechnology 3
Table 1: Currently reported TCR gene transfer attempts for hematological malignancies.
Target antigen HLA restriction vector Comments Transduction eﬃcacy Reference
WT1 HLA-A∗0201 retroviral
vector
WT1-speciﬁc TCR gene
was transduced into PBL.
CD8+ or CD4+ Tc e l l s
could exert target
speciﬁcity.
40∼60% in total T
c e l l sb yV b 2A ba f t e r2
rounds of
antigen-speciﬁc
stimulation
[8]
HLA-A∗0201
optimized
retroviral
vector
WT1-speciﬁc TCR gene
was modiﬁed to express
more eﬃciently (hybrid
human-murine TCR,
Cys-mutant TCR). Patients’
PBL transduced
WT1-speciﬁc TCR could
reject the engraftment of
autologous CML-BC cells
in NOD/SCID mice model.
conventional vector:
0.6% in total CD8+ T
cells by tetramer
(nonstimulated)
optimised vector: 6%
in total CD8+ Tc e l l s
by tetramer
(nonstimulated)
[26, 27]
HLA-A∗2402 lentiviral
vector
WT1-speciﬁc TCR gene
was transduced into PBL.
CD8+ or CD4+ Tc e l l s
could exert target
speciﬁcity in an HLA class
I-restricted fashion.
60% in total T cells by
Vb5.1 Ab
(nonstimulated) 20%
in sorted CD8+ Tc e l l s
by tetramer
[11]
HLA-A∗2402
optimized
retroviral
vector
The vector could suppress
endogenous TCR by
shRNA and increase
transduced
codon-optimized TCR
simultaneously.
44% in transduced
CD8+ Tc e l l sb y
tetramer
[28]
HA-1 HLA-A∗0201 retroviral
vector
HA-1-speciﬁc TCR gene
was transduced into T cells.
These transfectants could
exert target speciﬁcity.
6.6% in transduced T
cells by tetrameter
[9]
HA-2 HLA-A∗0201 retroviral
vector
HA-2-speciﬁc TCR gene
transduced CD8+ Tc e l l
clone was established.
These transfectants could
exert target speciﬁcity.
NA [10]
HLA-A∗0201 retroviral
vector
HA-2-speciﬁc TCR gene
was transduced into
CMV-speciﬁc CTL clone to
exploit the viral speciﬁc
response in vivo for the
long-term persistence of
target TCR transfectants.
NA [29]
Abbreviations: WT1, Wilms’ tumor gene product 1; PBL, peripheral blood lymphocytes; CML-BC, chronic myelogenous leukemia-blastic crisis; CMV,
cytomegalovirus; NA, not available; Ab, antibody.
using a retroviral system for which the transduction eﬃcacy
wasabout20%,asdeterminedbythedetectionoftransferred
V-β molecules or particular tetramers [8, 11, 32–35]. It was
found that TCR gene-transferred normal T cells expressed
the TCR heterodimer on the cell surface, conferring both
identical antigen speciﬁcity and HLA restriction.
Table 1 lists reported attempts at TCR gene transfer
for hematological malignancies. As can be seen, the use of4 Journal of Biomedicine and Biotechnology
this modality for treatment of hematological malignancies
still remains in its infancy. We have determined the HLA-
A∗2402 restricted 9mer-epitope derived from WT1 protein
(WT1235–243; CMTWNQMNL), and have demonstrated its
clinical usefulness as a leukemia vaccine [38, 39]. Simulta-
neously, we have established the CTL clone speciﬁc to this
epitope by HLA-A∗2402 restriction [38], and subsequently
described the in vitro feasibility of this WT1-speciﬁc TCR
gene transfer using a lentiviral vector [11]. For the purpose
of clinical application, we recently established a GMP-
grade bicistronic retroviral vector carrying the full-length
sequence of these TCR-α and β genes, and used it to
conﬁrm the speciﬁcity of the transferable HLA-A∗2402-
restricted epitope. Normal CD8+ T cells transferred with
this TCR gene successfully displayed an antileukemia eﬀect
via recognition of the target epitope on leukemia cells, and
normal CD4+ T cells harboring this transferred TCR gene
successfully displayed antileukemia Th1 helper function also
via recognition of the HLA-A∗2402-restricted target epitope
on leukemia cells (in preparation). Based on results from in
vitro and mouse experiments, we are preparing to carry out
clinical trials using these WT1-speciﬁc TCR gene-transferred
T cells against hematological malignancies and several solid
tumors.
Other preclinical attempts to investigate the feasibility
of antileukemia ACT using HLA-A∗0201-restricted WT1-
speciﬁc TCR and HLA-A∗0201-restricted HA-1/2-speciﬁc
TCR [9, 10] have also been reported. With regard to HLA-
A∗0201-restricted WT1-speciﬁc TCR, Stauss and colleagues
have technically succeeded in increasing WT1-speciﬁc TCR
on transduced T lymphocytes using genetic modiﬁcations,
and also in demonstrating the in vivo antileukemia eﬀect of
such engineered T cells using a murine system [8, 26].
4.ClinicalEfﬁcacy andAdverse Effects
ofACTUsing EngineeredTCells after
TCR Gene Transfer
Sofar,noresultsofclinicaltrialsoftherapyforhematological
malignancies using ACT with T cells harboring a TAA/TSA-
speciﬁc TCR gene have been reported. Therefore, reference
should be made to the results of pioneering clinical trials
of melanoma therapy performed by Rosenberg’s group,
who used adoptive transfer of MART-1-speciﬁc TCR gene-
transduced T cells in 17 patients with metastatic melanoma
[3]. In 15 of the 17 patients, the infused MART-1-speciﬁc
TCR gene-transferred T cells persisted for longer than two
months, at a level of more than 10% of total peripheral
lymphocytes.Two(11.8%)ofthe17patientsobtainedpartial
clinical remission, and their infused MART-1-speciﬁc T
cells persisted for longer than a year in the periphery and
retained their target-speciﬁcresponsiveness. The same group
has recently described better results in another clinical trial
using newly established MART-1 and gp100-speciﬁc TCR
genes with higher aﬃnities [2]. In that study, an objective
antimelanoma response, as deﬁned by the RECIST criteria,
was observed in 9 (25%) of 36 patients, and the clinical
eﬃcacy was again correlated with persistence of the infused
T cells, which maintained their target-speciﬁc response in
vivo. On the other hand, because MART-1 and gp100 are
shared by normal melanocytes, transferred engineered T
cells with high-aﬃnity TCRs for these antigens were able
to substantially damage normal melanocytes in the skin,
eyes, ears, and hair. Another important phase I clinical
trial using a preestablished allogeneic MART-1-speciﬁc TCR
gene-transduced CTL line (C Cure 709) against melanoma
was reported by Duval and colleagues [40]. The authors
administered irradiated C Cure 709 cells intratumorally. No
severe adverse events were observed, and 1 of 15 patients
experienced a partial response. In the remaining patients,
tumor reduction was observed not only at the injection site,
but also in other areas.
Collectively, ACT using TSA/TAA-speciﬁc TCR gene-
transferred T cells seems eﬀective and its toxicity depends
on the target antigen distribution in normal tissues and the
aﬃnity level of the transferred TCRs. If leukemia antigen-
speciﬁc TCR gene-transferred T cells are used for adoptive
therapy against leukemia, for example, high-aﬃnity WT1-
speciﬁc TCR gene-transferred T cells, attention should be
paid to any adverse eﬀects on WT1-expressing normal
tissues, especially the hematopoietic system. Further inves-
tigation of the potential therapeutic use of TSA/TAA-speciﬁc
TCR-transduced allogeneic T cells is warranted.
5. Attempts to Address CurrentProblems in
TCR-Engineered T-Cell Therapy
Although the engineering of T cells using TSA/TAA-speciﬁc
TCR gene transfer is an attractive strategy for redirecting
T cells towards malignancies, several issues still remain to
be overcome, and generally these can be divided into two
categories (Figure 1).
5.1. Improvement of Surface TCR Expression Eﬃcacy. TCR
α/β heterodimer cannot be properly expressed on the cell
surface when the CD3 molecule is absent [41]. The cell
surface expression of transduced TCR α/β heterodimer also
requires assembly with the γ, δ, ε,a n dζ chains of the
CD3 molecule. The competition between transduced and
endogenous TCRs for association with the CD3 molecule
determines the surface expression level of transduced TCR,
because the total amount of available CD3 molecules on
each T cell is predetermined. Recently, Heemskerk and
colleagues have demonstrated that the functional activity
of TCR-transduced T cells is correlated with TCR cell-
surface expression, and that introduced, endogenous, and
chimeric TCRs compete for cell-surface expression in favor
of the TCR-CD3 complex with optimal pairing properties
[42]. When considered simply, TCR assemblyand expression
involve two steps. Pairing of the TCR α and β chains is
postulatedtooccurﬁrst,followedbyassociationofthepaired
TCR chains with CD3 components. The latter step involves
interaction between the constant region of TCR and the
CD3 chains. As a corollary, manipulations to improve the
eﬃcacy of desired TCR α and β chain pairing and the CD3
assembly competition between transduced and endogenousJournal of Biomedicine and Biotechnology 5
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Figure 1: Reported modiﬁcations of TSA/TAA-speciﬁc TCR transduction. With the aim of enhancing the surface expression level of the
transduced TCR heterodimer, modiﬁcations are largely categorized into two options. One is to modify the target-TCR gene itself, and
the other is to transduce alternative cells other than normal peripheral T lymphocytes. The former involves the murine/human hybrid, a
modiﬁed two-chain TCR that encompasses total human CD3ζ, additional disulﬁde-bond insertion, codon modiﬁcation, and insertion of
built-in silencers for endogenous TCR. The latter involves TCR transduction into γδ T cells. These options aim to enhance the immediate
antitumor eﬀect of transfectants. On the other hand, TCR-gene transduction into hematopoietic stem cells is particularly aimed at achieving
the prolonged presence of transfectants, which will be able to provide a durable antitumor eﬀect.
TCRs would be expected to enhance the expression of the
intended TCR heterodimer in the genetically modiﬁed T
cells.
Based on this concept, there have been several attempts
to enhance the expression of the target TCR. Based on the
fact that murine TCR is expressed more eﬃciently in human
T cells than human TCR, replacing the human constant
regionwithmurinesequencestoyieldhybridmurine/human
constant region constructs leads to eﬃcient expression of
the hybrid TCR, without altering the speciﬁcity of the trans-
duced TCR [27, 43]. In addition, it has been demonstrated
that the hybrid TCR interacts with CD3 molecules with
higher aﬃnity than the human TCR, thus improving the
expression of the target TCR due to strengthened CD3
assembly competition.
An alternative strategy for improving the expression of
TCR is modiﬁcation of the TCR α/β interface, with the
aim of enhancing correct pairing between the transduced
TCR α/β chains, and reducing the extent of mispairing
between the transduced and endogenous TCRs. For this
purpose, introduction of additional cysteine residues into
the α and β chains to provide an additional disulﬁde bond
between the modiﬁed TCR chains has been attempted.
This resulted in more eﬃcient expression of the cysteine-
inserted TCR chains in comparison with the unmodiﬁed
ones, accompanied by a reduced degree of mispairing
between the transduced and endogenous TCRs [27, 44, 45].
To prevent this mispairing, Sebestyen and colleagues have
reported an intriguing strategy by using a modiﬁed two-
chain TCR that encompasses total human CD3ζ which
results in highly preferred pairing between CD3ζ-modiﬁed
TCR α and β chains as well as absence of TCR mispairing
between TCR:CD3ζ and nonmodiﬁed TCR chains. In this
article, authors demonstrated that transfer of both modiﬁed
TCRα:CD3ζ and TCRβ:CD3ζ chains resulted in high
surface expression, binding of peptide-MHC complexes and
antigen-speciﬁc T cell functions. In addition, this genetic
introduction of TCR α/β:ζ did not compromise surface
expression and functions of an endogenous TCR α/β [46].
Codon-optimization to increase the production of TCR α/β
proteins is another option to facilitate the surface expression
of transduced TCR. Codon modiﬁcation of TCR involves6 Journal of Biomedicine and Biotechnology
omission of mRNA instability motifs and cryptic splice sites,
resulting in increased expression of the TCR α/β chain in the
transduced CD8+ T cells, thus rendering the transfectants
functionally more active against target tumor cells [47].
In addition, we have recently reported a new technique
for improving the expression and reactivity of transduced
tumor-speciﬁc TCR by speciﬁc silencing of endogenous
TCR [28]. To reduce the degree of mispairing between
transduced and endogenous TCR, which can impair the
cell surface expression of the transduced TCR and result in
insuﬃcientfunctionandpotentialgenerationofautoreactive
T cells, we have developed retroviral vectors encoding both
small interfering RNA (siRNA) constructs, which speciﬁcally
down-regulate endogenous TCR, and a codon-optimized,
siRNA-resistant TCR speciﬁc for the human tumor antigens
MAGE-A4 or WT1. At a low copy number of the integrated
vector, the transduced human lymphocytes exhibited high
surface expression of the introduced tumor-speciﬁc TCR
and reduced expression of endogenous TCRs, resulting
in enhanced cytotoxic activity against antigen-expressing
tumor cells. We are now planning to conduct clinical trials of
antitumor adoptive therapy using T cells engineered by these
vectors [28].
To avoid this mispairing between tranduced and endoge-
nous TCR, the introduction of a TCR gene into γ/δ T cells,
which originally lack an endogenous TCR, is also a promis-
ing option. Minor histocompatibility antigen HA-2-speciﬁc
TCR, cytomegalovirus (CMV)-speciﬁc TCR, or MAGE-
A4-speciﬁc TCR-transduced peripheral blood-derived γδ
T cells have been demonstrated to exert target-speciﬁc
cytotoxicity and cytokine production. Because γδ Tc e l l sd o
not express the CD4 or CD8 molecule, cointroduction of
these coreceptor molecules suﬃciently facilitates the target-
speciﬁcreactivityofTCRα/β-transducedγ/δ Tcells[48,49].
5.2. Facilitation of a Long-Lasting Functional Memory Respo-
nse of TCR-Transduced T Cells. The endeavors described
above to improve the cell-surface expression of transduced
TCR genes have been harnessed to potentiate the imme-
diate antitumor activity of the transfectants. Although the
causative factors have not been fully determined, it has been
demonstrated that such engineered T cells soon lose their
surfaceexpression of transduced TCR [50]. Thus, to preserve
a durable antitumor eﬀect, especially for the prevention of
disease relapse in patients with cancer, methods to maintain
the introduced TCR expression should be developed. For
example, exploitation of the memory T-cell response against
latent cytomegalovirus (CMV) infection has been attempted
for the expansion of HA-2-speciﬁc TCR-gene-transduced T
cells [29]. An HA-2-speciﬁc TCR-gene-transduced CMV-
speciﬁc CTL clone exerted dual cytotoxicity against both
CMVpp65 antigen and HA-2-positive leukemia cells ex vivo.
It was anticipated that these transfectants would exploit
the virus-speciﬁc response to maintain both their survival
and antitumor activity. Recently, tumor-reactive chimeric
antigen receptor (CAR) gene-transduced Epstein-Barr virus
(EBV)-speciﬁc CTLs applied for the treatment of indi-
viduals with neuroblastoma have displayed the anticipated
persistence and antitumor activity [51]. As is observed in
ACT with ex vivo-expanded tumor-speciﬁc T cells [52],
for the long-term survival of TAA/TSA-speciﬁc TCR-gene-
transduced T cells in vivo, the central memory fraction of
such transfectants is considered to be important. However,
using a murine model, Hinrichs et al. have recently revealed
that na¨ ıve T cells are a better target of TSA/TAA-speciﬁc
TCR gene transfer than central memory T cells for achieving
long-lasting and active antitumor activity in vivo [53]. The
authors reported that after repetitive stimulation, TCR-gene-
transduced central memory T cells were more prone to rapid
senescence than gene-modiﬁed na¨ ıve T cells, resulting in
shorterandweakerantitumoractivityinvivo.Therefore,iso-
latedCD62L+CD45RO−na¨ ıveTcellsfromleukemiapatients’
leukapheresis samples could provide a better platform for T-
cell engineering by TAA/TSA-speciﬁc TCR gene transfer.
For the long-term survival of TAA/TSA-speciﬁc TCR-
gene-transduced T cells in vivo, TCR gene transfer to
hematopoietic stem cells, which would be able to medi-
ate continuous T-cell production through homeostatic
hematopoiesis, seems attractive. To address the feasibility of
this option, TCR gene-transduced hematopoietic stem cells
were cultured with OP9 stromal cells expressing the Notch
human ligand Delta-like 1 (OP9-DL1) in vitro, allowing
stem cells to diﬀerentiate into mature T cells [54, 55].
Although several limitations still remain, the diﬀerentiated T
cells obtained with this OP9-DL1 culture system, expressing
transduced TCRs, were easily expandable and successfully
exerted cytotoxicity against target cells in vitro. However,
it still remains to be clariﬁed whether such TAA/TSA-
speciﬁc TCR gene-transduced T cells can diﬀerentiate in the
circulation through the normal thymic education system.
Beforeclinical application, it willﬁrst be necessary to address
the concern about the potential risk of leukemogenesis
caused by retroviral-vector-mediated uncontrolled “shot-
gun” gene insertion into hematopoietic stem cells. Lessons
have been learned from the clinical application of suicide-
gene (HVS-TK)-inserted donor lymphocyte infusion for the
treatment of patients with relapsed leukemia after allo-
HSCT,inwhomundesirablyfunctioningdonorlymphocytes
were clinically reduced in number using ganciclovir [56–
58], suggesting that this option could be considered for
eradicating such undesirable cells generated from genetically
manipulated hematopoietic stem cells. Furthermore, long-
termfollow-upgenome-wideanalysisofTlymphocytesfrom
patients who have received DLI using retrovirally HSV-
TK gene-inserted donor lymphocytes has revealed that the
transduced T-cell populations maintained remarkably stable
gene expression proﬁles, phenotype, biological functions,
and immune repertoire in vivo, with no evidence of clonal
selection up to 9 years after administration. The authors
suggested that integrations interfering with normal T-cell
function were more likely to lead to clonal ablation than
expansion in vivo [59]. These observations suggest that as
long as TAA/TSA-speciﬁc TCR genes are retrovirally inserted
into the peripheral mature T-cell genome, there would be
little concern regarding safety. There have been some recent
articles describing the feasibility of hematopoietic stem cells
as a target of gene therapy [60–62]. Although these linesJournal of Biomedicine and Biotechnology 7
of evidence suggest that hematopoietic stem cells can be
considered for TCR-gene transfer, this option is still in its
infancy as far as clinical application is concerned.
6. SummaryandFutureDirections
Substantial progress has been made in clarifying the required
conditions for the achievement of eﬃcient antitumor adop-
tive therapy, especially with the use of TAA/TSA-speciﬁc
TCR gene-transferred T cells, although this has been largely
achieved from studies of melanoma and viral infections.
In other words, as far as clinical application to leukemia
is concerned, and for disseminated leukemia in particular,
it still remains unclear whether engineered T-cell therapy
could be clinically eﬀective. Unlike antileukemia peptide
vaccination, adoptive therapy with engineered T cells is
advantageous in that a suﬃcient number of tumor-speciﬁc
CTLs can be prepared, that is, disseminated leukemia should
be the good target of this option. In fact, Dossett and
colleagues have recently demonstrated the in vivo eﬃcacy
of ex vivo expanded and adoptively transferred TSA-speciﬁc
TCR gene-transduced T cells against disseminated leukemia
in a murine model [63]. This result provides considerable
encouragement for the promotion of WT1-speciﬁc TCR
gene-transferred T-cell therapy for human leukemia, and
indeed we are shortly to conduct a phase I clinical trial using
WT1-speciﬁc TCR gene-transferred T cells for the treatment
of patients with hematological malignancy.
On the other hand, leukemia is a formidable adversary,
and comprehensive strategies must be developed for durable
control of the disease. As it has been mentioned, therapy
using engineered T cells is still in its infancy, and to achieve
long-term eﬃcacy, peptide vaccination following TCR-gene-
transduced T-cell therapy is a reasonable option for restim-
ulating such transferred engineered T cells towards “mem-
ory T cells”. Alternatively, small-molecule inhibitor therapy
targeting a molecule identical to that in TCR-gene therapy,
which plays an important role in tumorigenesis, also appears
to have promise for achieving a less toxic and more eﬀective
strategy for durable control of leukemia. As a model for the
latter option, we are investigating the feasibility of Aurora A
kinase-speciﬁc TCR gene-transferred T-cell therapy followed
by Aurora A kinase inhibitor therapy [64]. We have recently
identiﬁed that Aurora A kinase, which is widely expressed in
various types of cancer, is a novel tumor target antigen for
immunotherapyagainstleukemia[65].Wehaveidentiﬁedan
HLA-A∗0201-restrictedantigenicepitopeofAuroraAkinase
capable of inducing leukemia-reactive CTL, and established
an epitope-speciﬁc TCR gene-expressing retroviral vector
for TCR-gene-transferred T-cell therapy [66]; currently we
are investigating the feasibility of a combination of Aurora
A kinase-speciﬁc TCR gene-transferred T-cell therapy and
Aurora A kinase inhibitor therapy.
Finally, it is relevant to mention our future plan for
engineered T-cell therapy using TCR gene transfer for the
treatment of hematological malignancy. This strategy orig-
inally requires prior determination of the TAA/TSA-speciﬁc
TCR, which means that determination of the antigenic epi-
tope, HLA-restriction, and establishment of the CTL clone
must all be done beforehand. Therefore, it is fundamentally
diﬃcult to prepare multiple TCRs for diﬀerent TAA/TSA
with diﬀerent HLA restrictions. We have already determined
the HLA-A∗2402-restricted antigenic epitope from human
telomerasereversetranscriptase(hTERT),whichisoneofthe
best-known tumor antigens, and also established a TCR gene
from hTERT-speciﬁc CTL clones [67], in addition to WT1
and Aurora A kinase. These prepared multiple TCRs make
it possible to provide more adequate TCR for each patient
according to the individual’s HLA type and tumor antigen
expression proﬁle, that is, so-called “tailor-made” TCR ther-
apy for each individual. Collectively, gene immunotherapy
using TSA/TAA-speciﬁc TCR is an attractive option for
hematological malignancies, although multiple drawbacks
still need to be overcome. In order to improve the eﬃcacy
of this strategy, it is undisputed that further clinical trials
are necessary to reveal tumor-derived and/or host-derived
characteristics that disable TCR gene-transduced tumor-
reactive T cells. Based on these endeavors, it is anticipated
thatgeneimmunotherapyusingTAA/TSA-speciﬁcTCRgene
transfer to T cells will open a new door for the treatment of
hematological malignancies in the near future.
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